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The histone deacetylase inhibiting 
drug Entinostat induces lipid 
accumulation in differentiated 
HepaRG cells
Abigail D. G. Nunn1,2, Tullio Scopigno1,2, Natalia Pediconi3, Massimo Levrero1,4,5,6, 
Henning Hagman7, Juris Kiskis7 & Annika Enejder7
Dietary overload of toxic, free metabolic intermediates leads to disrupted insulin signalling and fatty 
liver disease. However, it was recently reported that this pathway might not be universal: depletion of 
histone deacetylase (HDAC) enhances insulin sensitivity alongside hepatic lipid accumulation in mice, 
but the mechanistic role of microscopic lipid structure in this effect remains unclear. Here we study the 
effect of Entinostat, a synthetic HDAC inhibitor undergoing clinical trials, on hepatic lipid metabolism in 
the paradigmatic HepaRG liver cell line. Specifically, we statistically quantify lipid droplet morphology 
at single cell level utilizing label-free microscopy, coherent anti-Stokes Raman scattering, supported 
by gene expression. We observe Entinostat efficiently rerouting carbohydrates and free-fatty acids into 
lipid droplets, upregulating lipid coat protein gene Plin4, and relocating droplets nearer to the nucleus. 
Our results demonstrate the power of Entinostat to promote lipid synthesis and storage, allowing 
reduced systemic sugar levels and sequestration of toxic metabolites within protected protein-coated 
droplets, suggesting a potential therapeutic strategy for diseases such as diabetes and metabolic 
syndrome.
Acetylation of lysine residues in proteins has emerged as a ubiquitous mechanism for reversible, post-translational 
modification of protein functionality and activity, being modulated by two counteracting types of enzymes in 
response to cellular signalling: histone acetyltransferases (HATs) and histone deacetylases (HDACs). These were 
first discovered as key actors in the epigenetic machinery, modulating gene expression by altering the acetylation 
of histones in chromatin affecting the compactness of the DNA-histone complex and hence the binding of tran-
scription factors1,2. However, it soon became clear that the functionality of many non-histone proteins located in 
the nucleus was also modulated by their acetylation pattern, such as proteins involved in pathways controlling 
apoptosis, cell cycle progression, redox pathways, mitotic division, DNA repair, and cell migration. Not so sur-
prisingly, altered expression of HATs and HDACs has been reported in association with a number of human 
diseases such as cancer, inflammatory and neurodegenerative diseases3.
Recently, HDACs have also been shown to modulate metabolic pathways in the liver; inhibition upregulates 
genes coding for de novo lipogenesis and lipid sequestration together with down-regulating gluconeogenesis4,5. 
Improved tolerance to glucose and higher insulin sensitivity were reported, suggesting HDAC inhibition as a 
promising target for therapeutic intervention in diabetes, metabolic syndrome and related diseases. Hepatic 
lipid accumulation is, in long-term perspective, harmful for the functionality of the liver, but at over-nutrition 
it has been shown to have a beneficial impact by safely sequestering excess toxic metabolites in perilipin-coated 
lipid droplets, clearing cellular free-fatty acids and intermediates that would otherwise cause damage to insulin 
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signalling and create cardiovascular risk6. These new aspects of lysine acetylation as a metabolic modulator moti-
vate studies of the impact of synthetic HDAC inhibitors on hepatic lipid metabolism: such drugs can potentially 
offer novel therapeutic solutions for diseases that affect a large proportion of the population and they reside 
among the most promising classes of drugs currently under clinical evaluation.
In this work we study the effect of the HDAC inhibitor Entinostat (MS275), which is already in clinical trials 
for cancer treatment, on hepatic lipid metabolism in HepaRG cells by quantifying lipid store droplets and their 
distribution at single cell level utilizing a label-free microscopy technique, coherent anti-Stokes Raman scat-
tering (CARS). HepaRG is a human liver cell line that upon differentiation exhibits characteristics of primary 
human hepatocytes and therefore offers a good representation of human hepatic xenobiotic metabolism7. CARS 
microscopy, like Raman microscopy8, enables chemically specific label-free image contrast for cellular lipids. Use 
of the strong CH2 symmetric stretching vibration at around 2840 cm−1, in a coherent Raman excitation scheme 
allows pico(10−12)-gram sensitivity and sub-micron spatial resolution at high speeds, avoiding problems that can 
be associated with the use of perturbatively large fluorescent labels or stains9,10. Here we present analysis, using 
three-dimensional and subcellular spatial information from CARS images, of the effect of the HDAC inhibiting 
drug Entinostat, comparing differentiated HepaRG (dHepaRG) cells that have undergone three treatments: i, 
Entinostat, ii, fatty acid overload (sodium oleate) and iii, Entinostat and fatty acid overload in combination, as 
well as a control. Addition of oleate salts to the cell culture medium allows rapid access to lipids without need of 
de novo fatty acid synthesis, inducing lipid storage by enzymatic regulation, which we compared with the lipid 
accumulation mechanisms observed after addition of the drug Entinostat, inducing de novo lipid synthesis via 
gene regulation. We reveal contrasting modes of lipid droplet loading for the treatments, correlating image sta-
tistics with gene expression data. We demonstrate that Entinostat induces the sequestration of lipid droplets 
with increased lipid coat proteins, highlighting the potentialities of Entinostat and inhibitors of HDACs in the 
treatment of metabolic syndrome.
Results
CARS images of cells exposed to different conditions (control, Entinostat treatment, oleate overload and 
Entinostat combined with oleate overload) show significantly different patterns of lipid accumulation (Fig. 1), 
in the absence of significant cell toxicity (Supplementary Fig. 1). All of the treatments (Fig. 1b–d) result in an 
increase in average lipid droplet numbers compared to the untreated cells (Fig. 1a). A quite uniform increase in 
lipid droplet numbers across all cells is apparent as a result of Entinostat intake (Fig. 1b), whereas for the oleate 
treated cells, the cell-to-cell variability is large: there appears a strong increase in the lipid levels in some cells, and 
a lesser increase in others (Fig. 1c). For the combined treatment very strong loading with lipid droplets is induced 
consistently in almost all cells (Fig. 1d).
Lipid droplet numbers and volumes increase dramatically with treatment. Quantitative image 
analyses of the lipid droplet volumes and areas based on a statistically significant number of cells per treatment 
Figure 1. Different modes of lipid accumulation. Examples of CARS images of control cells (no treatment) 
(a), cells treated with Entinostat (b), cells treated with oleic acid overload (c), cells treated with both oleic acid 
overload and Entinostat (d). Entire fields of view are shown on the left, and insets with cell outlines overlaid on 
the right. Entinostat induces a moderate degree of lipid droplet accumulation across almost all cells (b), whereas 
with oleate (free fatty acid), there is significant increase in lipid accumulation in some cells, observed as higher 
numbers of lipid droplets per cell as well as larger volumes of individual droplets; two examples of different 
lipid structure accumulation are shown in the expansion in (c). Entinostat treatment under conditions of excess 
metabolite availability results in a strong lipid loading in almost all cells (d). Images are single planes taken from 
z-stacks, displayed after noise removal using PureDenoise (see Materials and Methods). Scale bars for images  
are 30 μ m and 10 μ m for expansions.
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category are summarized in Fig. 2a. In Fig. 2b,c we see that the number of droplets per cell, as well as the total lipid 
volume per cell, increases strongly with either treatment by Entinostat or oleate overload compared to the control 
cells, and further increases with the combined treatment of drug and oleate. Total lipid volumes for the different 
treatments acquired from the CARS microscopy images are in agreement with measured lipid amounts from 
fluorescence activated cell sorting (FACS) analysis using bodipy (Supplementary Fig. 2). For both the number of 
droplets per cell and the sum of lipid droplet volumes per cell, Wilcoxon rank-sum tests between all the different 
cell treatment conditions result in rejection of the null hypothesis for every pair of treatments, including the drug 
only and oleate only pair, indicating that the treatment populations vary significantly in these two statistical prop-
erties, at the 1% significance level. The median number of droplets per cell for the combined treatment is 199, and 
for the Entinostat and oleate single treatments it is 121 and 96 respectively, implying an approximately additive 
effect for the treatments. However, the effect for total lipid volume per cell is not additive: the median volume for 
the combined treatment is 536 μ m3, for Entinostat only it is 103 μ m3, and for oleate it is 152 μ m3.
Lipid droplet size variation. Statistically, a greater cell-to-cell uniformity of lipid droplet accumulation 
with Entinostat compared to oleate overload is highlighted in the cluster plot in Fig. 2e, where we show the pop-
ulations as cellular median droplet radius versus droplet count per cell: the larger variation of median droplet 
radius across the cell population for the oleate treatment is apparent. We highlight three main groups for this 
cell population: one group (the largest) that occupies the same space in the scatter plot as the Entinostat treated 
cells, with intermediate median cell radii (highlighted in the plot by a solid-lined blue circle), another with small 
median droplet radii (dashed blue circle), and another with high values of median droplet radii (dotted blue 
circle). The population that was treated by the drug and oleate overload maintains the uniformity of the drug 
treatment but is shifted to significantly larger median droplet size and higher droplet count. The main popu-
lations of the Entinostat and oleate individual treatments show a trend of increasing number of lipid droplets 
per cell with increasing median droplet radius, indicating a population of growing lipid droplets in the cells. In 
contrast, the combined treatment shows an approximate trend of reduced number of lipid droplets with increas-
ing median droplet radius, which could perhaps indicate that this population is in a state in which lipid droplet 
fusion is dominant. In Fig. 2f–i the bimodal distributions of radii of all lipid droplets for the different treatments 
are shown. They have a symmetric, almost Gaussian-like, peak shape between 0.2 and 0.8 μ m, accompanied by a 
peak representing droplets with a radius < 0.2 μ m. The peaks at low values indicate the presence of budding lipid 
droplets, which are probably formed as precursors to other droplets11,12. For the control cells, the median (and 
half interquartile range) value of the droplet radii is 0.22(0.15) μ m. Although the effect of the drug and of the 
oleate overload (Fig. 2g,h) seems at first glance, in these truncated plots, to be similar in terms of the droplet size 
distribution, with a peak at values of radius ~0.4 μ m in both cases, if we define three different categories of droplet 
sizes based on the structures of the distributions (budding, r < 0.2 μ m; growing 0.2 < r < 0.8 μ m; large, r < 0.8 μ m), 
looking at the percentage of larger droplets (r > 0.8 μ m, also beyond the truncated histogram plots) we notice 
that this population is smaller for Entinostat treatment. So, with carbohydrates as energy source (Entinostat 
treatment), the proportion of these large droplets remains at 2.7%, as for the control, compared to fatty acid treat-
ment in which the percentage is approximately tripled to 7.9%. For the combined treatment (Fig. 2i), the huge 
increase in total lipid volume can be described by two effects: (i) an increasing population of growing droplets 
(0.2 < r < 0.8 μ m, 78.3%), all of which slightly larger, as evidenced by the shift in the peak of the radii distribution 
to ~0.45 μ m, and (ii) a substantial increase in the number of large droplets (r > 0.8 μ m, 13.3%).
Droplet fusion and hints about growth dynamics. In Fig. 2i, the larger proportion of large lipid drop-
lets in the combined treatment population (r > 0.8 μ m, 13%) might result from fusion of individual smaller drop-
lets. Studies by Boström et al. indicate that lipid droplets with larger size can result from fusion of small droplets, 
typically arriving towards the centre of the nucleus from the outer regions of the cell and then merging with 
neighbours13. Figure 2e provides some clues to the dynamics of lipid droplet growth in our cell study; we see that 
the cells for the combined treatment occupy a region of approximately negative trend, the more lipid droplets, the 
smaller the median droplet size and vice versa, by contrast, the Entinostat only treatment has an approximately 
positive trend such that more lipid droplet counts in a cell means a larger median droplet size. This suggests that 
the two treatment populations might have been imaged at two different stages of growth: in the drug only, the 
population is still “growing” overall, at the end of the 4 day incubation period, so that most of the droplets con-
tinued to increase in size probably by in situ triglyceride synthesis, whereas in the combined treatment, the cells 
are likely to be already saturated with lipids, so perhaps to conserve space or phospholipid membrane molecules, 
significant numbers of droplet fusion events have taken place after the individual expansion stage12.
Subcellular droplet location and in situ triglyceride synthesis. Statistical spatial analysis over the 
whole imaged cell population reveals that the median distance between lipid droplets and cell nucleus is larger for 
the oleate treated cells (8.0 μ m) than it is for the other treatments (6.4 and 6.8 μ m for the Entinostat treated and 
Entinostat and oleate treated cells respectively); this is despite the median nuclear radius being similar for all three 
samples (6.7, 6.4 and 6.5 μ m for Entinostat, oleate, and combined treatments respectively), and the median cell 
area being considerably smaller for the oleate treated cells compared to the others (990 versus 1484 and 1427 μ m2 
for Entinostat and the combined treatments respectively, see Supplementary Figs 3 and 4 for more details of 
nuclear and cell sizes). Scatter plots showing the full distributions (truncated in Fig. 2f–i), of the lipid droplets’ 
sizes and their distances from the nucleus edge are shown in Fig. 3. These plots show the populations of lipid 
droplets from all cells, illustrating the substantial and similar collections of larger lipid droplets (r > 0.8 μ m) for 
the categories with access to excess fatty acids. Figure 3 also reveals a slight negative trend of droplet size and 
distance from the nucleus – larger droplets (r > 0.8 μ m) in all treatment cases and the control can be seen nearer 
the nucleus. This trend becomes more pronounced in the case of the combined treatment, where in some cells 
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(such as the example illustrated in the inset of Fig. 3d) we see a negative gradient of droplet dimension as the 
distance from the nucleus increases. We can also see from this plot that the combined treatment of Entinostat 
and oleate overload induces the spreading of the population of medium-sized droplets to much larger (50–70 μ m) 
Figure 2. Results of quantitative image analysis of lipid droplet properties of HepaRG cells. Summary 
table showing the median and interquartile range for three cellular quantities derived from image analysis, 
and breakdown of droplet populations across all cells into size categories, budding (r < 0.2 μ m), growing 
(0.2 < r < 0.8 μ m) and large (r > 0.8 μ m) (a). Box and whisker plots of the number of droplets per cell (b) and the 
total lipid volume per cell (c). Scatter of the total lipid droplet volume versus the lipid droplet count (d) shows 
that oleic acid enables the storage of large lipid volumes in fewer droplets, with or without co-incubation with 
Entinostat, also seen in the plot expansion inset. Median droplet radius versus the lipid droplet count (truncated, e) 
reveals three main groups, highlighted by the overlaid solid-lined circles: 1-untreated, 2-single treatments 
(either drug or oleate) and 3-the combined treatment; the higher degree of cell-to-cell variability for the non-
drug treated cells is apparent in this plot, where two subgroups of the oleate single treatment are also circled, 
one with low droplet count and small median droplet radius (dashed line) and one with low droplet count and 
large median radius (dotted line); an approximate trend of increasing number of droplets with radius size for the 
single Entinostat treatment but the reverse relationship for the combined treatment could be related to droplet 
fusion levels. Truncated histograms showing the distribution of droplet radii from all cells, with the numbers 
of budding, growing and large droplets overlaid (f–i). For drug treatment an increase in lipid volume, as for the 
oleate treatment, occurs but along with a higher average number of droplets than the oleate treatment; for the 
combined treatment, the strong loading of the cells with lipids results in the highest number of droplets and 
much increased total lipid volume, manifesting as a substantial increase in the relative proportion of growing 
and large droplets. The colour scheme and cell counts for all plots is given in (b). For (b,c), thick horizontal bars 
represent means, boxes mark 25th, 50th and 75th percentiles, and whiskers indicate standard deviations.
www.nature.com/scientificreports/
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distances from the nucleus. However, as noted above, the average location of the droplets in this treatment case is 
still nearer the nucleus than for the oleate overload treatment alone; the population at longer distances is only a 
small outgrowth of the main peri-nuclear droplet population. Relative dispersions of the droplets within the cell 
are illustrated by examples shown inset in Fig. 3.
Wilfling et al. recently reported the existence of two different classes of lipid droplets, “static” and “expanding” 
lipid droplets (sLDs and eLDs), that were observed after treatment of cells with oleic acid. eLDs were found to 
contain an important enzyme for triglyceride biosynthesis (GPAT4), which relocated to the droplets from the 
endoplasmic reticulum (ER) after the addition of oleic acid. So-called eLDs are therefore able to expand rapidly 
under the conditions of excess fatty acid by in situ triglyceride synthesis, whereas the sLDs remained a smaller 
uniform size, presumably because they had no access to the ER and therefore also to the triglyceride synthesis 
enzymes14. This pattern of behaviour is echoed in our images, where, as seen in Fig. 3, the overall trend is for 
larger lipid droplets always to be in peri-nuclear locations, where the density of ER is greatest. Furthermore, we 
can hypothesize that the two different populations of droplets that we see in the cells, under all treatments, bud-
ding (r < 0.2 μ m), and growing (0.2 < r < 0.8 μ m) could be associated with these two types of static and expanding 
lipid droplets (Fig. 2f–i). In this context, the effect of Entinostat in maintaining, on average, droplet populations 
nearer the nucleus (median distance to nucleus of droplet is 6.4, 8.0 and 6.8 μ m for Entinostat, oleate and com-
bined treatments respectively, also see Fig. 3) implies, as we observe, a super-efficient capacity for uptake of the 
fatty acids and in situ conversion into triglycerides in the combined treatment because most of the droplets are 
within easy reach of the ER. This mechanism could contribute, alongside the droplet fusion hypothesis discussed 
above, to the presence of the large number of large droplets in the combined treatment. Furthermore, Kassan et al. 
report that the growth of lipid droplets is dependent on free-fatty acid concentration but the number of droplets is 
independent of this15, which agrees with our median cellular lipid volume increase in the combined treatment of 
nearly 2000-fold, but only a 30-fold increase in droplet numbers with respect to the control. A time-lapse imaging 
study of the effect of Entinostat on lipid droplet growth could elucidate further details of the dynamics of forma-
tion and growth, by fusion and/or by in situ triglyceride synthesis, and would also aid our understanding of the 
biomedical implications use of this drug, observing the effect of drug removal in cells as a model for understand-
ing the longer-term effects in the liver of Entinostat after treatment is completed.
Figure 3. Intracellular droplet dispersion.  Scatter plots of distance to nucleus edge from droplet centroid 
versus droplet radius for all droplets in entire cell sample reveal a slight trend of inverse relationship of droplet 
size with distance from nucleus in control (a), Entinostat (b) and oleate (c) cells; for Entinostat and oleate 
treatment (d), this trend becomes more distinct in some cells, as shown inset. For this combined treatment, 
increased numbers of medium-sized droplets results in more dispersion of these droplets away from the nucleus 
but the average droplet distance from the nucleus is greatest for the oleate treatment alone; the median cell radii 
dimension is shown as a dashed horizontal line on each subplot, which helps to highlight the greater dispersion 
within the cells – more droplets further from the nucleus – associated with fatty acid overload compared 
to treatment with only Entinostat. Insets qualitatively illustrate the different loadings of budding (r > 0.2 μ 
m, yellow), growing (0.2 < r < 0.8 μ m, orange) and large (r > 0.8 μ m, red) droplets for example cells, and the 
difference in their locations relative to the overlaid cell boundary and nuclear edge, with more dispersion for 
oleate treatment apparent (scale bars 5 μ m).
www.nature.com/scientificreports/
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Lipid droplet coat protein and de novo lipogenesis gene expression upregulated. To further 
understand the changes in patterns of lipid droplet formation in the context of the histone de-acetylase inhibi-
tion caused by Entinostat, we carried out a gene expression analysis on treated HepaRG cells (Fig. 4). It confirms 
the observations made by CARS microscopy on the lipid droplet morphologies and distributions; a significant 
upregulation of Scd and Fasn (de novo lipogenesis) can be noted combined with an upregulation of Plin4, related 
to the budding of lipid droplets16. Entinostat treatment at oleate overload approximately doubles the upregulation 
of Scd and Plin4, but also induces a manifest upregulation of Gpam (promoting triglyceride synthesis) as well as 
increased expression of Plin2 (significant for mature lipid droplets). Oleate overload alone targets primarily the 
metabolic enzymes and shows a relatively small impact at gene expression level beside a four-fold upregulation of 
Plin2 related to the formation of mature lipid droplets16–18.
The upregulation of both Scd and Fasn, genes for de novo FA synthesis, with Entinostat treatment are in full 
agreement with the work of Sun et al. in which HDAC3 depletion was clearly linked to a rerouting of metabolites 
towards lipid synthesis and away from glucose synthesis, with a resultant increase in insulin sensitivity5. Scd 
encodes the protein Stearoyl-CoA desaturase which is responsible for producing unsaturated oleic acid from 
saturated stearic acid, and Fasn encodes fatty acid synthase which produces the saturated fatty acid palmitate. 
We see upregulation of Fasn in the presence of Entinostat, only without free fatty acid (FFA) overload, hence the 
combined effect of the two treatments seems to be suppression of the synthesis of the saturated FA in favour of the 
unsaturated one. Overloading hepatic cells with oleate has been reported to induce down-regulation of lipogene-
sis genes including Scd, as per our results for the oleate incubation alone19. Acacb and Gpam are examples of genes 
associated with triglyceride synthesis and the inhibition of Acyl-CoA transference to mitochondria, and thus our 
observation of upregulation of these genes alongside lipid accumulation with all treatments (Fig. 4) indicates that 
fatty acid oxidation is dominated by fatty acid synthesis5.
Although expression of the gene in healthy liver cells is absent, Cidec (Cell Death-Inducing DFFA-Like 
Effector C), which codes for the lipid coat protein Fat-specific protein 27, has been observed in the liver after fast-
ing or high-fat diet in mice, and its upregulation has been associated with large lipid droplets in adipocytes20,21. 
Here (Fig. 4) we see only a slight upregulation of Cidec by single treatments with oleate and or Entinostat, possibly 
as the amount of FFAs was not sufficient to induce the formation of giant lipid droplets. Upregulation of Plin2, 
coding for the lipid coat protein Perilipin 2 (Plin2), has been reported to be associated with an upregulation of 
SNARE protein SNAP23, which promotes lipid droplet fusion22. This agrees well with our observation (Fig. 4) of 
increased expression of Plin2 at fatty acid overload (both with and without co-treatment with Entinostat) where 
we saw a substantial increase in the number of large droplets (r > 0.8 μ m), up to 8% and 13% for oleate alone 
and Entinostat co-treatments respectively, compared to just 2.7% for both the Entinostat only and control pop-
ulations. While Plin2 has been reported to be localised later in the droplet formation process, on medium-sized 
droplets, Plin4 (also called S3-12) facilitates the very early stage formation of small lipid droplets16–18. The man-
ifest upregulation of Plin4, for cells treated with Entinostat, both without, and even more strongly, with excess 
FFAs, correlates with the increased median number of droplets per cell we observe (121 and 199 for Entinostat 
and combined treatments respectively, compared to 96 at oleate overload): Plin4 appears then to be important for 
droplet formation in our sample under inhibition of HDACs. This observation is also in line with the qualitative 
observation of Sun et al., who noted the accumulation of small droplets with HDAC deletion5. The magnitude 
of the overexpression of Plin4 (> eight-fold compared to the control), with Entinostat or combined treatment is 
so strong that perhaps we could expect to see even higher numbers of droplets seeded, and a possible reason we 
do not could be insufficient amounts of cholesterol esters, a minor component of hepatic lipids, but which have 
recently been noted to be preferentially associated with by Plin417,19,23. Several studies have focussed on the role of 
Figure 4. Results of Real-time PCR analysis. De novo lipogenesis (Scd, Fasn), triglyceride synthesis (Acacb, 
Gpam), and lipid sequestration (Cidec, Plin2, Plin4); data are expressed as fold induction (treated versus 
untreated). Free fatty acid (FFA, oleate) overload shows a minor impact at gene expression level, except for a 
~four-fold upregulation of the gene that encodes for the protein Perilipin 2 (Plin2), which coats mature lipid 
droplets. Entinostat induces a significant upregulation of genes involved in de novo lipogenesis (Scd, Fasn) and 
the gene (Plin4) for the protein Perilipin 4, coating emerging lipid droplets. Finally, for Entinostat treatment with 
access to FFAs a combination of the upregulated genes (Scd, Plin2 and Plin4) can be observed complemented by 
Gpam, inhibiting the transport of acyl-CoA into mitochondria hence promoting triglyceride synthesis. Each bar 
represents the mean of three independent experiments [horizontal bar marks p-value < 0.005].
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Plin2 in liver steatosis5,24–26, whereas our results bring to light the potential importance of Plin4, as well as Plin2, 
and thus future studies of hepatic lipid storage mechanisms, and hence insulin sensitivity, could be more clearly 
understood taking into account Plin4 availability.
Discussion
Over-nutrition results in an overload of different free metabolic intermediates known to be toxic and eventually 
leads to disruption of systemic insulin signalling27. However, if the intermediates are converted to triglycerides 
and sequestered as in perilipin-coated droplets in the liver, it has been shown that insulin resistance in mice can 
be reduced albeit with the development of hepatosteatosis6. Hdac3 knock-out in the liver can promote the storage 
of lipids in droplets by rerouting metabolic precursors toward lipid synthesis and storage, resulting in higher 
insulin sensitivity5. This renders Class I HDAC inhibitors, such as Entinostat, interesting candidates for treatment 
of metabolic diseases and it highlights the need for better understanding of mechanisms behind the formation of 
hepatic lipid store droplets.
Beside modulation of the cell metabolism via gene expression, lysine acetylation has also been shown to be 
vital downstream. In response to different carbon sources, it controls the activation and inhibition of almost all 
cytoplasmic and mitochondrial enzymes involved in gluconeogenesis, glycolysis, the glycogen-, fatty acid- and 
nitrogen metabolism, assuring a more prompt feed-back loop, enabling the cell or organism to sense current 
energy status and immediately adapt to varying nutritional conditions28,29. Upregulation of the genes associated 
with lipid synthesis and sequestration (Fig. 4) allows us to conclude that the steatotic effect of Entinostat is caused 
at least in part, and perhaps primarily, by histone de-acetylation at the gene expression level5. However, we cannot 
rule out the possibility that lipid accumulation with Entinostat treatment occurs also due to de-acetylation of the 
enzymes in the glycolysis, gluconeogenesis, the tricarboxylic acid (TCA) cycle, fatty acid metabolism, and/or 
glycogen metabolism as during lipid load described by Zhao et al.29. A complete picture of the processes that 
lead to cellular lipid accumulation by Entinostat treatment could be derived from a high-throughput microarray 
for acetylation and deacetylation profiling and its correlation with a genome wide analysis of promoter bound 
lysine-acetylated-histones by ChipSeq. Whereas the primary target for Entinostat is gene regulation, the pri-
mary targets for oleate overload are enzymes regulating metabolism, as shown by the minimal response at gene 
expression level at oleate overload. Cell size differences (Fig. 2a) may be linked to the effect of lysine acetylation 
on cytoskeleton reorganisation28. Furthermore, as an HDAC1 (as well as HDAC3) inhibitor, Entinostat can have 
an effect on cell proliferation and growth. An investigation into the effects of Entinostat on lipid metabolism and 
insulin sensitivity in a diabetic mouse model carried out by Galmozzi et al.30 found, in contrast to our results, and 
another study31, no changes in hepatic gene expression after treatment, and lipid accumulation in the diabetic 
mouse model was cleared. Our results describe the effect of Entinostat in a non-transformed human hepatocytic 
cell line where features and properties of adult human hepatocytes are conserved, and hence could represent a 
better indication of the effect of HDAC inhibition on the human liver than transgenic animal models.
The decreased cell-to-cell variability with Entinostat treatment, with or without co-treatment with oleic acid, 
is marked: the interquartile range of the cellular lipid volume is significantly reduced in the presence of Entinostat 
(Fig. 2a,c), and the scatter of median droplet radius and droplet counts per cell is more uniform (Fig. 2e). 
Entinostat appears to induce lipid accumulation across all cells, overriding intrinsic cellular metabolic differences. 
This implies that it might have the capacity to relocate lipids already accumulated in the liver, storing them more 
safely, which bodes well for the possibility of its use in lipid storage induction as a treatment strategy.
In conclusion, we have shown that a specific HDAC inhibitor drug already in clinical trials for cancer treat-
ment may be of use as a therapy for other epidemiologically important diseases. We see a particular pattern of 
uniform cell-to-cell increase in lipid droplet sequestration in a human liver cell model after incubation with 
Entinostat. The drug promotes the storage of metabolites as lipid droplets, both when the energy source is purely 
carbohydrates as well as at fatty acid overload; this provides a good basis for further investigation of Entinostat as 
a potential candidate for the treatment of diabetes and obesity. Upregulation of perilipin genes indicates that the 
droplets might be protected from immediate degradation, but the lipid morphology induced by the drug – small 
droplets, near to the nucleus – allows accessibility to lipolytic enzymes, which means the lipid storage is poten-
tially reversible in the long-term. Intrahepatic fat accumulation, if left unchecked, can lead to the more advanced 
non-alcoholic steatohepatitis (NASH), which may progress to cirrhosis and, in a small percentage of patients, to 
hepatocellular carcinoma (HCC). However, only in a small percentage of patients (0–2.8%) will NASH progress 
to end-stage liver disease such as cirrhosis and HCC over a 19.5-year period, and therefore, as lipid accumulation 
is a reversible process it need not necessarily have a significant immediate negative impact on patient health32. 
Hence the induction of reversible safe lipid droplet accumulation in the liver by short-term administration of 
Entinostat or similar Class I HDAC inhibitors, temporarily and rapidly removing toxic free fatty acids from 
the cells and reducing the load of carbohydrates in the bloodstream that would otherwise interfere with insulin 
signalling, may provide a window of therapeutic opportunity to allow commencement of longer-term treatment 
strategies for obesity and metabolic disease such as changes in diet and exercise.
Materials and Methods
Cell preparation. Human hepatoma HepaRG cells were seeded at a density of 2.6 × 104 cells/cm2 in William’s 
E medium with GlutamaX (GiBco) supplemented with 10% fetal bovine serum, 100 U/mL penicillin, 100 μ g/mL 
streptomycin, 5 μ g/mL insulin and 50 μ M hydrocortisone hemi-succinate. In one week cells reached confluence 
with a doubling time of around 24 h and were shifted to the same medium supplemented with 2% dimethyl sulfoxide 
(DMSO) for a further two weeks to obtain confluent differentiated cultures33. After differentiation, HepaRG cells 
were incubated for 4 days with a solution of either sodium oleate (250 μ M), Entinostat (8 μ M), both sodium oleate 
(250 μ M) and Entinostat (8 μ M) or control. Three separate cell culture dishes were prepared for each treatment 
condition. After the period of incubation, the cells were fixed with 4% formaldehyde ready for imaging. The 
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optimal conditions (dosage and incubation time) for fatty acid overload induction of vesicular steatosis in dHep-
aRG, as demonstrated by FACS analysis with BODIPY staining for neutral lipids, was established in preliminary 
experiments using 100, 250 and 500 μ M of sodium oleate for 1, 2, 4 and 6 days. Entinostat dosage of 8 μ M was 
chosen according to the manufacturer’s instructions (Selleckchem).
CARS microscopy. A multimodal nonlinear microscope was used to record 3D stacks of images in the fixed 
cells, using the strong CH vibration at 2840 cm−1 of the lipids as image contrast. Details of the microscope may 
be obtained elsewhere34. In brief, a picosecond laser source (Levante Emerald OPO, APE Angewandte Physik & 
Elektronik GmbH, Germany, pumped by a Nd:Vanadate laser at 1064 nm, High Q Laser GmbH, Austria) generated 
two pulses at 76 MHz repetition rate, with powers of 50 mW and 120 mW for the pump (817 nm) and Stokes 
(1064 nm) beams, that were spatially and temporally overlapped and then coupled to a modified inverted laser 
scanning confocal microscope. A 40× /NA = 1.3 oil immersion objective was used to focus the light for imaging 
over a square field of 200 μ m with lateral pixel size 0.098 μ m (2048 × 2048 pixels) and create z-stacks with an axial 
spacing of 0.3 μ m. The pixel dwell time was 9.6 μ s. The CARS signal in the forward direction was collected with 
an aspheric lens (Thorlabs AL2520-B, NA = 0.54, WD = 15.7 mm) and detected using a photomultiplier tube 
connected to a time-correlated single photon counting unit (HPM-100-40 connected to an SPC-150 module card, 
Becker & Hickl GmbH, Germany) after filtering appropriately: first a long pass dichroic mirror (FF775-Di01, 
Semrock Inc., USA) was used to separate the excitation beams from the CARS signal (emitted at 663 nm) followed 
by two short pass 790 nm filters (Semrock FF01-790/SP) blocking any remaining reflected excitation light and 
finally a band pass filter centred at 661 nm with 20 nm of bandwidth (Semrock FF01-661/20) to further clean and 
eliminate any fluorescence emitted by the sample.
Image processing and analysis. All image processing and analysis was carried out using the Fiji imple-
mentation of ImageJ, supplemented also by MATLAB scripts. In total, three-dimensional z-stacks covering the 
entire volume of a total of 267 control cells, 165 cells treated with Entinostat, 230 cells treated with oleate, and 
167 cells treated with the combination of oleate and Entinostat were imaged. The experiments were conducted 
with three replicates for each of these categories (three separate dishes per category). Analysis was performed on 
> 50 cells from image stacks of each of the three replicates of each treatment condition: n = 85, 102, 80 for control 
cells; n = 72, 81 and 77 for oleate treated cell; n = 52, 59 and 56 for combined oleate and Entinostat treated cells; 
and n = 53, 61 and 51 for Entinostat treated cells. These cell counts represent all the cells imaged in each of three 
images (for control and oleate treated cells) or five images (for combined oleate and Entinostat and Entinostat 
only treatments).
The images were corrected for saturation of a few pixels using the known dead time of the detection unit 
(MATLAB). Before carrying out analysis of the lipid structures in the cells, the z-stacks of images were smoothed 
using the PureDenoise algorithm plugin for ImageJ35, which allowed effective removal of noise, and then cor-
rected for differences in the laser power.
In order to obtain cell-to-cell statistics on the lipid content, image stacks were laterally divided into stacks for 
single cells. This also facilitated the optimal selection of threshold for the volumetric and area analysis, which 
was slightly dependent on the position within the field of view (Fiji ImageJ). For the single cell analysis in 3D, 
the 3D object counting routine in ImageJ was run on every cell separately, to retrieve volumes for all droplets 
which were summed to give the cellular lipid volume. For some data, such as the lipid droplet counts, a 2D 
analysis, which included using a watershed algorithm to effectively discriminate adjacent particles was used (see 
Supplementary Information for more details on this aspect). For the 2D analysis, selection of a single xy image 
from the brightest section of each cell was followed by segmentation of each cell into droplets and background 
by thresholding, setting the threshold by inspection of each cell separately (Fiji ImageJ). The Watershed function 
in Fiji ImageJ was also used, allowing the counting of separate adjacent lipid droplets by subsequent use of the 
ImageJ Measure function from which the droplet areas and centroid coordinates were also obtained. These were 
used to compute the droplet counts per cell, and the droplet radii, as well as the distance of droplet centroids from 
the nuclei; some justification of the use of single plane images for the computation of these quantities is given in 
the Supplementary Information and in Supplementary Figs 5–7. Cell area masks and cell nuclei masks were also 
determined from inspection of the 2D plane images for each cell. These were then used to compute the cell area 
and the droplet to nucleus edge distance. Radii for cells, nuclei and droplets were all computed as averages from 
the measured areas of these particles. For both the single plane and 3D counting, no lower limit on the number 
of pixels per droplet was set.
Box-and-whisker plots, scatter plots and histograms (Figs 2 and 3) were created using Origin. For each pop-
ulation in all the box-and-whisker plots presented here, box upper and lower limits are the 25th and 75th per-
centiles, the median is the horizontal line through the box, the mean is thicker horizontal line, and the upper and 
lower limits of the vertical whiskers are ± 1 standard deviation of the mean.
PCR analysis. Total cellular RNAs were extracted from cells treated as described above using TRIzol reagent 
(Gibco BRL), and 1 μ g was reverse transcribed with the ThermoScript reverse transcription (RT)-PCR system 
(Invitrogen). cDNAs were quantified by real-time PCR analysis (Light Cycler; Roche Diagnostics) using gene 
specific primers shown in the Table in Supplementary Fig. 8. The 18S ribosomal RNA was used to normalize the 
RNA samples. Relative expression was calculated using the comparative Ct method (2−ΔCp, Δ Cp = Cp (target 
gene) - Cp (18S)). Data are expressed as fold induction (treated vs untreated) of 2−ΔCp mean (Fig. 4).
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lipid accumulation in differentiated 
HepaRG cells
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In the original Supplementary Information file published with this Article, the y-axis label for Supplementary 
Figure 2 was omitted. This has now been updated to read ‘Mean Fluorescence Intensity’.
This error has been corrected in the Supplementary Information that now accompanies the Article.
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